Ginsburg, P. B., B. C. Strunk, M. I. Banker, and J. P. Cookson. 2006. Tracking health care costs: Continued stability but at high rates in 2005. Health Affairs (Millwood) 25(6): w486-w495.

Hartman, M., A. Martin, P. McDonnell, and A. Catlin. 2009. National health spending in 2007: Slower drug spending contributes to lowest rate of overall growth since 1998. Health Affairs (Millwood) 28(1):246-261.

Hoadley, J. 2007. The Prescription drug safety net: Access to pharmaceuticals for the uninsured. National Health Policy Forum, May 9, Washington, DC.

Hoerger, T., S. Karon, S. Bernard, K. Tate, R. Lindrooth, T. Waters, and K. Jewell. 2003. Evaluation of Medicare’s competitive bidding demonstration for DMEPOS: Final evaluation report. Research Triangle Park, NC: RTI International.

IMS Health. 2006. Method of Payment Report. Norwalk: IMS Health.

Jayadev, R., and J. Stiglitz. 2009. Two ideas to increase innovation and reduce pharmaceutical costs and prices. Health Affairs (Millwood) 28(1):w165-w168.

Joyce, G. F., J. J. Escarce, M. D. Solomon, and D. P. Goldman. 2002. Employer drug benefit plans and spending on prescription drugs. Journal of the American Medical Association 288(14):1733-1739.

Keeler, E. B., G. Melnick, and J. Zwanziger. 1999. The changing effects of competition on non-profit and for-profit hospital pricing behavior. Journal of Health Economics 18(1):69-86.

Lerner, J. C., D. M. Fox, J. Reiss, and T. Nelson. 2008. Perspective: The consequences of secret prices: The politics of physician preference items. Health Affairs (Millwood) 27(6):1560-1565.

MedCo Health. 2009. Drug Trend Report 2009. Chicago: MedCo Health.

MedPAC. 2009. Report to the Congress: Improving Incentives in the Medicare Program. Washington, DC.

Nelson, T. 2007. Personal communication with Timothy B. Strachan. Grinnell, May 25, 2009.

Paris, V., and E. Docteur. 2006. Pharmaceutical pricing and reimbursement policies in Canada. Paris: Organisation for Economic Co-operation and Development.

Pauly, M. V., and L. R. Burns. 2008. Price transparency for medical devices. Health Affairs (Millwood) 27(6):1544-1553.

Purvis, L. 2009. Rx Watchdog Report: Trends in manufacturer prices of prescription drugs used by medicare beneficiaries: 2008 Year-end update. Washington, DC: AARP Public Policy Institute.

Schneller, E. S. 2009. The value of group purchasing-2009: Meeting the needs for strategic savings. http://www.gpossavemoney.org/ValueofGPO-2009.pdf (accessed April 26, 2009).

Siegfried, R. 2007. Personal conversation with Timothy B. Strachan. Newark, May.

Strunk, B. C., P. B. Ginsburg, and J. R. Gabel. 2002. Tracking health care costs: Growth accelerates again in 2001. Health Affairs (Millwood) Suppl Web Exclusives:w299-w310.

Town, R., and G. Vistnes. 2001. Hospital competition in HMO networks. Journal of Health Economics 20(5):733-753.

Town, R., D. Wholey, R. Feldman, and L. Burns. 2006. The welfare consequences of hospital mergers. Cambridge: National Bureau or Economic Research.

U.S. Congress. 2009. Medicare’s DMEPOS competitive bidding program. Washington, DC: Subcommittee on Health of the Committee on Ways and Means. http://waysandmeans.house.gov/hearings.asp?formmode=view&id=7569 (accessed June 12, 2009).

Vita, M., and S. Sacher. 2001. The competitive effects of not-for-profit hospital mergers: A case study. Journal of Industrial Economics 49(1).

Vogt, W., and R. Town. 2006. How Has Hospital Consolidation Affected the Price and Quality of Hospital Care? Princeton: Robert Wood Johnson Foundation.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement